Kineta (Private) expertise in innate immunity and immunology. Wholly owned preclinical anti-VISTA antibody reprograms the tumor microenvironment and is differentiated from other immunotherapies by blocking suppressive cells in cold tumors. VISTA is the most highly expressed checkpoint in hard to treat tumors. Signed 2 large early stage partnering deals in 2018 - $520M deal with Pfizer for its small molecule RIG-I immunotherapy that elicits a dual mechanism to turn cold (checkpoint resistant) tumors hot; and a $360M+ deal with Genentech for KCP506, a first in class a9/a10 Nicotinic Acetylcholine Receptor (nAChR) antagonist - preclinical, non-opioid for chronic pain. LHF-535 in Ph1 for the treatment of Lassa Fever wholly funded by Wellcome Trust (priority review voucher upon approval).